SpringerLink
Log in

Immune checkpoint inhibitor colitis: the flip side of the wonder drugs

  • Invited Annual Review Issue
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Immune checkpoint inhibitors block the co-inhibitory receptors on T cells to activate their cytotoxic immune function and are rapidly being explored for the treatment of various advanced-stage malignancies. These novel drugs have already significantly increased survival rates. The first available immune checkpoint inhibitors were cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors (such as ipilimumab), followed by programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) inhibitors (such as pembrolizumab and nivolumab). Anti-PD-1 and anti-PD-L1 therapies have demonstrated better efficacy and tolerability and less severe adverse effects compared to anti-CTLA-4 agents. Idelalisib, a PI3Kδ isoform inhibitor, is another immunotherapeutic agent that is often classified separately and is currently used in treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomas. Despite successful therapeutic responses, immune-related adverse events have been reported with the use of these agents. The gastrointestinal side effects, particularly diarrhea, are among the most commonly reported symptoms. The histologic features of immune checkpoint inhibitor-associated colitis show a spectrum of patterns of injury among various drug classes. There is significant overlap between immune checkpoint inhibitor-associated colitis and other colitides, making the differential diagnosis difficult—especially in the absence of clinical history. The histopathology data on immune checkpoint inhibitor-associated colitis are limited. Here we review clinical features as well as various histologic patterns of colitis associated with these groups of medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588(2):368–376. https://doi.org/10.1016/j.febslet.2013.10.015

    CAS  PubMed  Google Scholar 

  2. Dolan DE, Gupta S (2014) PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 21(3):231–237. https://doi.org/10.1177/107327481402100308

    PubMed  Google Scholar 

  3. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz l Jr et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275–287. https://doi.org/10.1038/nrc.2016.36

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007. https://doi.org/10.1056/NEJMoa1315226

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD (2016) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 27(7):1362. https://doi.org/10.1093/annonc/mdw141

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824

    PubMed  Google Scholar 

  8. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148. https://doi.org/10.1016/j.ejca.2015.11.016

    CAS  PubMed  Google Scholar 

  9. Mitchel KA, Kluger H, Sznol M, Hartman DJ (2013) Ipilimumab-induced perforating colitis. J Clin Gastroenterol 47(9):781–785. https://doi.org/10.1097/MCG.0b013e31828f1d51

    Google Scholar 

  10. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240. https://doi.org/10.1001/jamaoncol.2015.4368

    PubMed  Google Scholar 

  11. Chen JH, Pezhouh MK, Lauwers GY, Masia R (2017) Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol 41(5):643–654. https://doi.org/10.1097/PAS.0000000000000829

    PubMed  Google Scholar 

  12. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY (2008) α-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 32(8):1130–1137. https://doi.org/10.1097/PAS.0b013e31817150e3

    PubMed  Google Scholar 

  13. Gupta A, De Felice KM, Loftus EV, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42(4):406–417. https://doi.org/10.1111/apt.13281

    CAS  PubMed  Google Scholar 

  14. Weidner A-S, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, Jessurun J, Yantiss RK (2015) Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol 39(12):1661–1667. https://doi.org/10.1097/PAS.0000000000000522

    PubMed  Google Scholar 

  15. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C (2017) PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology 70(4):558–567. https://doi.org/10.1111/his.13118

    PubMed  Google Scholar 

  16. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129(2):512–521. https://doi.org/10.1016/j.gastro.2005.05.006

    PubMed  Google Scholar 

  17. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–209. https://doi.org/10.1016/j.ejca.2016.02.025

    CAS  PubMed  Google Scholar 

  18. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675–1682. https://doi.org/10.1002/cncr.27969

    CAS  PubMed  Google Scholar 

  19. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4(14):272. 10.21037/atm.2016.07.10

    PubMed  PubMed Central  Google Scholar 

  21. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbe C (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164. https://doi.org/10.1016/S1470-2045(09)70334-1

    CAS  PubMed  Google Scholar 

  22. Villadolid J, Amin A (2015) Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4(5):560–575. https://doi.org/10.3978/j.issn.2218-6751.2015.06.06

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: Clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol 39(12):1653–1660. https://doi.org/10.1097/PAS.0000000000000525

    PubMed  Google Scholar 

  24. McDermott DF, Atkins MB (2013) PD-1 as a potential target in cancer therapy. Cancer Med 2(5):662–673. https://doi.org/10.1002/cam4.106

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643. https://doi.org/10.1182/blood-2007-11-123141

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297–339. https://doi.org/10.1016/S0065-2776(06)90008-X

    CAS  PubMed  PubMed Central  Google Scholar 

  27. West NR, Powrie F (2015) Immunotherapy not working? Check your microbiota. Cancer Cell 28(6):687–689. https://doi.org/10.1016/j.ccell.2015.11.010

    CAS  PubMed  Google Scholar 

  28. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD et al (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94(9):4330–4335. https://doi.org/10.1073/pnas.94.9.4330

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Hude I, Sasse S, Engert A, Bröckelmann PJ (2017) The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 102(1):30–42. https://doi.org/10.3324/haematol.2016.150656

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB et al (2010) Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 55(5):1396–1405. https://doi.org/10.1007/s10620-009-0839-8

    PubMed  Google Scholar 

  31. Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK et al (2016) Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 14(6):836–842. https://doi.org/10.1016/j.cgh.2015.12.028

    PubMed  Google Scholar 

  32. Bavi P, Butler M, Serra S, Chetty R (2017) Immune modulator-induced changes in the gastrointestinal tract. Histopathology 71(3):494–496. https://doi.org/10.1111/his.13224

    PubMed  Google Scholar 

  33. Baroudjian B, Lourenco N, Pages C, Chami I, Maillet M, Bertheau P, Bagot M, Gornet JM, Lebbe C, Allez M (2016) Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res 26(3):308–311. https://doi.org/10.1097/CMR.0000000000000252

    CAS  PubMed  Google Scholar 

  34. Marginean EC (2016) The ever-changing landscape of drug-induced injury of the lower gastrointestinal tract. Arch Pathol Lab Med 140(8):748–758. https://doi.org/10.5858/arpa.2015-0451-RA

    CAS  PubMed  Google Scholar 

  35. Arnold CA, Lam-Himlin DM, Montgomery E (2015) Atlas of gastrointestinal pathology: a pattern based approach to non-neoplastic biopsies. Wolters Kluwer Health, Philadelphia

    Google Scholar 

  36. Beck KE, Blansfield JA, Tran KQ, Feldman a, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24(15):2283–2289. https://doi.org/10.1200/JCO.2005.04.5716

    CAS  PubMed  Google Scholar 

  37. Fecher LA, Agarwala SS, Hodi FS, Weber JS (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18(6):733–743. https://doi.org/10.1634/theoncologist.2012-0483

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Fay AP, Moreira RB, Nunes Filho PR, Albuquerque C, Barrios CH (2016) The management of immune-related adverse events associated with immune checkpoint blockade. Expert Rev Qual Life Cancer Care 1(1):89–97. https://doi.org/10.1080/23809000.2016.1142827

    Google Scholar 

  39. Johnston RL, Lutzky J, Chodhry A, Barkin JS (2009) Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 54(11):2538–2540. https://doi.org/10.1007/s10620-008-0641-z

    CAS  PubMed  Google Scholar 

  40. Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099. https://doi.org/10.1200/JCO.2014.60.0379

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Vieth M, Montgomery E (2017) Medication-associated gastrointestinal tract injury. Virchows Arch 470(3):245–266. https://doi.org/10.1007/s00428-017-2077-3

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Florida, Gainesville, USA

    Naziheh Assarzadegan

  2. Johns Hopkins Medical Institutions, Baltimore, USA

    Elizabeth Montgomery & Robert A. Anders

Authors
  1. Naziheh Assarzadegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Anders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naziheh Assarzadegan.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Assarzadegan, N., Montgomery, E. & Anders, R.A. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch 472, 125–133 (2018). https://doi.org/10.1007/s00428-017-2267-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2267-z

Keywords

Search

Navigation